开云app官网登录入口网页版-官方正版

#IL-17#

68篇内容 | 2480人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2163062, encodeId=6dfe2163062b2, content=<a href='/topic/show?id=dd5813562e5' target=_blank style='color:#2F92EE;'>#OX40#</a><a href='/topic/show?id=07a69996557' target=_blank style='color:#2F92EE;'>#靶点#</a>可能成为<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>新的明星靶点! <a href='/topic/show?id=597010e014a8' target=_blank style='color:#2F92EE;'>#OX40L单抗#</a><a href='/topic/show?id=10c010e015ac' target=_blank style='color:#2F92EE;'>#amlitelimab#</a>的临床试验IIb达到主要终点。此前<a href='/topic/show?id=f68a10e01698' target=_blank style='color:#2F92EE;'>#Rocatinlimab#</a>同样效果不俗。使得特应性皮炎，从<a href='/topic/show?id=0377963352' target=_blank style='color:#2F92EE;'>#IL-13#</a>， <a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>， <a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>等不同的靶点，进一步拓展至OX40L，未来可能对于单一治疗效果不好的病人，可以多药联用，有望取得更好的效果。另外，还有必要开发针对婴幼儿的特应性皮炎的治疗，这是临床刚需。 <a href='/topic/show?id=e9846644229' target=_blank style='color:#2F92EE;'>#湿疹#</a>, objectTitle=OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点, objectType=article, longId=796440, objectId=8e91e9644062, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230930/2b4e70e4d38248488b6c4dfee3c353b8.jpg, objectUrl=/article/show_article.do?id=8e91e9644062, replyNumber=0, likeNumber=111, createdTime=2023-10-16, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8e91e9644062, moduleTitle=OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8e91e9644062)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1374458, encodeId=731913e445860, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, objectType=article, longId=736657, objectId=c691e366579d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c691e366579d, replyNumber=0, likeNumber=106, createdTime=2022-08-24, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c691e366579d, moduleTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c691e366579d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374457, encodeId=a3ba13e4457cf, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, objectType=article, longId=724388, objectId=4e89e24388b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e89e24388b1, replyNumber=0, likeNumber=85, createdTime=2022-04-17, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e89e24388b1, moduleTitle=Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4e89e24388b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374456, encodeId=602e13e4456e1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染, objectType=article, longId=300605, objectId=849a30060505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849a30060505, replyNumber=0, likeNumber=78, createdTime=2022-03-14, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849a30060505, moduleTitle=Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=849a30060505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374455, encodeId=1c0713e445525, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路, objectType=article, longId=300087, objectId=8e5930008e1a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5930008e1a, replyNumber=0, likeNumber=96, createdTime=2022-03-06, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5930008e1a, moduleTitle=Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8e5930008e1a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374454, encodeId=d28513e4454e2, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, objectType=article, longId=294569, objectId=656829456957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656829456957, replyNumber=0, likeNumber=80, createdTime=2022-01-25, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656829456957, moduleTitle=UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=656829456957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374453, encodeId=f34113e4453d0, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节, objectType=article, longId=219328, objectId=722021932816, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=722021932816, replyNumber=0, likeNumber=83, createdTime=2021-10-28, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=722021932816, moduleTitle=J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=722021932816)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374452, encodeId=04b913e445201, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Arthritis Res Ther：IL-17抑制剂治疗强直性脊柱炎的疗效和安全性如何？, objectType=article, longId=210764, objectId=061a210e6467, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=061a210e6467, replyNumber=0, likeNumber=114, createdTime=2021-05-05, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=061a210e6467, moduleTitle=Arthritis Res Ther：IL-17抑制剂治疗强直性脊柱炎的疗效和安全性如何？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=061a210e6467)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374451, encodeId=447813e44516a, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, objectType=article, longId=210523, objectId=496421052350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=496421052350, replyNumber=0, likeNumber=82, createdTime=2021-04-28, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=496421052350, moduleTitle=Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=496421052350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374450, encodeId=e52713e4450d7, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=BMC Gastroenterology：血浆中IL-17和甲胎蛋白的水平可有效预测肝硬化患者发生肝癌的风险, objectType=article, longId=210172, objectId=d8312101e256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8312101e256, replyNumber=0, likeNumber=100, createdTime=2021-04-20, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8312101e256, moduleTitle=BMC Gastroenterology：血浆中IL-17和甲胎蛋白的水平可有效预测肝硬化患者发生肝癌的风险, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d8312101e256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374449, encodeId=8b4f13e4449ff, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验, objectType=article, longId=203507, objectId=ccd220350e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd220350e2c, replyNumber=0, likeNumber=68, createdTime=2020-11-19, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd220350e2c, moduleTitle=恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ccd220350e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374448, encodeId=f8cf13e44484f, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善, objectType=article, longId=203363, objectId=1f8720336334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8720336334, replyNumber=0, likeNumber=87, createdTime=2020-11-15, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8720336334, moduleTitle=Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1f8720336334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374447, encodeId=559e13e44474f, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, objectType=article, longId=202989, objectId=b8be20298966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8be20298966, replyNumber=0, likeNumber=67, createdTime=2020-11-08, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8be20298966, moduleTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b8be20298966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374446, encodeId=907213e44468f, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, objectType=article, longId=202790, objectId=00a7202e904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a7202e904b, replyNumber=0, likeNumber=72, createdTime=2020-11-04, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a7202e904b, moduleTitle=头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=00a7202e904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374445, encodeId=0cda13e444553, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=J Allergy Clin Immunol：高IL-17型哮喘患者具有银屑病免疫表型, objectType=article, longId=201429, objectId=9c2b20142981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c2b20142981, replyNumber=0, likeNumber=77, createdTime=2020-10-02, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c2b20142981, moduleTitle=J Allergy Clin Immunol：高IL-17型哮喘患者具有银屑病免疫表型, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9c2b20142981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374444, encodeId=a13913e4444f6, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, objectType=article, longId=198732, objectId=59fb198e32ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fb198e32ce, replyNumber=0, likeNumber=165, createdTime=2020-08-06, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fb198e32ce, moduleTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=59fb198e32ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374443, encodeId=ed8113e44436b, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=61, createdTime=2020-07-20, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374442, encodeId=95dd13e4442f2, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=196068, objectId=36e6196068e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e6196068e4, replyNumber=0, likeNumber=76, createdTime=2020-06-19, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e6196068e4, moduleTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=36e6196068e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374441, encodeId=d28b13e444142, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=64, createdTime=2020-06-15, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374440, encodeId=1d0313e444071, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=135, createdTime=2020-06-06, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

IL-17

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #OX40##靶点#可能成为#特应性皮炎#新的明星靶点! #OX40L单抗##amlitelimab#的临床试验IIb达到主要终点。此前#Rocatinlimab#同样效果不俗。使得特应性皮炎，从#IL-13#， #IL-17#， #IL-21#等不同的靶点，进一步拓展至OX40L，未来可能对于单一治疗效果不好的病人，可以多药联用，有望取得更好的效果。另外，还有必要开发针对婴幼儿的特应性皮炎的治疗，这是临床刚需。 #湿疹#

OX40靶点可能成为特应性皮炎新的明星靶点! OX40L单抗amlitelimab的临床试验IIb达到主要终点

2023-10-16发表于上海

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率

2022-08-24

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Crit Care：伴有AKI的危重患者血清IL-17水平较高且与患者较差预后相关

2022-04-17

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Front Immunol：IL-17加重慢性阻塞性肺疾病急性加重期铜绿假单胞菌呼吸道感染

2022-03-14

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Br J Dermatol：Brodaluma阻断 IL-17RA可减少化脓性汗腺炎皮肤和血清中的炎症通路

2022-03-06

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

UCB正在寻求IL-17A 和 IL-17F 双重抑制剂Bimzelx在银屑病关节炎中的批准

2022-01-25

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

J Invest Dermatol：IL-17A产生细胞在皮肤炎性疾病中的调节

2021-10-28

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Arthritis Res Ther：IL-17抑制剂治疗强直性脊柱炎的疗效和安全性如何？

2021-05-05

医者仁心 (审核中...)

前往app查看评论内容

#IL-17#

Lancet：IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功

2021-04-28

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

BMC Gastroenterology：血浆中IL-17和甲胎蛋白的水平可有效预测肝硬化患者发生肝癌的风险

2021-04-20

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

恒瑞 IL-17A单抗SHR-1314用于强直性脊柱炎获批临床试验

2020-11-19

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Can J Cardiol：与环孢素或甲氨蝶呤治疗相比，抑制IL-17A可使血管和心肌功能得到更大的改善

2020-11-15

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎

2020-11-08

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

头对头3期临床证实：抗IL-17单抗Bimekizumab治疗中度至重度银屑病优于TNF单抗修美乐

2020-11-04

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

J Allergy Clin Immunol：高IL-17型哮喘患者具有银屑病免疫表型

2020-10-02

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者

2020-08-06

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎

2020-06-19

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-06-15

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

科室
- - 订阅+
  - 更多科室
工具
服务